Bédard and colleagues, in their Research Letter
1 (this issue p. 133), inappropriately conclude that the SIMARD MD does not have a "high degree of accuracy" and is not an improvement over other screening tools for identifying cognitively impaired drivers. (In the version of the Bédard et al letter we received for response, those authors referred to 4 receiver-operating characteristic [ROC] curves in the text. However, the accompanying Figure 1 displayed only two ROC curves. The discrepancy between their text and the ROC plots is not clear.) The authors base their conclusion, in large part, on a comparison of ROC curves from two data points they indicate are derived from Dobbs and Schopflocher's Screen for the Identification of Cognitively Impaired Medically At-Risk Drivers, A Modification of the DemTect (SIMARD MD) findings 2 to two data points from an incompletely described combination of data from the standardized Mini-Mental Status Evaluation (MMSE) and Trails A from a previously published study (see Bédard et al. 2008) 3 . There are a number of methodological flaws with the Bédard et al 1 comparison that invalidate their conclusions. The most egregious error is their use of ROC curves to compare the predictive properties of the SIMARD MD to the predictive properties of other tests, when the findings are based on different criterion measures and different populations.
In addition to its use in assessing the predictive properties of a test, ROC curve analysis can be used to compare the predictive properties of different tests. However, fundamental to ROC curve analysis, when used to compare tests, is the use of the same sample or samples from the same population, and using the same outcome variable (ie, the same criterion). Thus, a valid comparison of the SIMARD MD to other screening tests requires ROC curve analyses using data from the different tests (eg, Trails A, the standardized MMSE, and the SIMARD MD) that have been administered to the same population (eg, using the same participants), with the outcome measure consistent across participants. Ignoring these requirements is like comparing apples to oranges. Bédard et al's comparison (see Figure 1 ) presents ROC curves from two different tests: (A) two cut points from some type of combination of time scores from the Trail Making Test Part A and accuracy scores from the standardized MMSE and (B) two cut points for the SIMARD MD, putatively derived from the Dobbs and Schopflocher publication. 2 However, the two studies used different criteria (road outcomes from what appears to be a standard novice driver road test in the Bédard et al study 1 vs pass/fail outcomes from an on-road driving assessment specifically developed to assess cognitively impaired drivers in the Dobbs and Schopflocher studies 2 ). In addition, the two tests were evaluated using different populations (a sample of drivers who "volunteered to participate" [p 337] in the 2008 Bédard et al study, 3 compared to a mix of drivers diagnosed with cognitive impairment with or without dementia [about twothirds of the sample] and healthy controls [about one-third of the sample] in the Dobbs and Schopflocher studies 2 ). Because these differences in the criteria and populations invalidate all of their test comparisons, the differences in the criteria and populations are detailed below.
In the development of the SIMARD MD, the suitability of the criterion to match the goals of the study was a critical issue. The driving criterion was selected because it isolated competence errors demonstrated to be associated with cognitively impaired drivers and excluded errors caused not by competency decline, but to errors that result from "bad driving habits".presumably competent drivers suggests there is a problem with the driving evaluation used as the driver competence criterion, which in turn calls into question the validity of the Bédard et al data presented in the ROC curves (see Figure 1 on). 1 Thus, not only are the criteria different, but Bédard et al rely on a criterion that is questionable (it fails well over half of the sample of drivers for whom there is little reason to suspect competence impairments), leaving one wondering about the value of those data for evaluating any screening test.
The study populations used by Dobbs and Schopflocher 2 and by Bédard et al 1,3 also have substantially different characteristics and must be regarded as different populations. Careful consideration was given to the selection of the population for the Dobbs and Schopflocher studies. 2 The average age of the participants was 77 in the initial study and 75 for the validation study, with the majority of the sample (81% and 79%, respectively) cognitively impaired. These sample characteristics were selected because they are representative of the population for which the tool was designed (patients seen in the clinical setting for concerns about cognitive driving competence and/or patients coming in for driver medicals). All that is known about the Bédard et al population is that the participants were from convenience samples aged 55 and over "who volunteered to participate . . . for self-evaluation purposes, in preparation for relicensing examination" (p. 337), 3 with no demographic or clinical data provided. Thus, Bédard et al rely on data from an exclusively nonclinical sample and draw conclusions about the clinical utility of those tools. 1 Given that the samples used for the SIMARD MD studies are representative of the clinical population for which the screening tool is intended to be used, the reservations of Bédard et al 1 concerning the SIMARD MD samples are not convincing.
In developing the SIMARD MD, we were mindful of the time restrictions of physicians. The SIMARD MD is a nonproprietary test requiring about 5 minutes to administer plus 1 minute of scoring time, approximately one-third of the time required to administer and score Trails A and the standardized MMSE. Moreover, the MMSE is now a proprietary test with a per-use cost, which adds to the complexity of use.
Finally, we should note that one important use of an ROC curve is to allow policy makers to determine the appropriate level of tradeoff between false positives (individuals who would fail the screening test but pass an appropriate on-road assessment) and false negatives (individuals who would pass a screening test but fail an appropriate onroad assessment), in combination with other concerns. Designating arbitrary levels of sensitivity/specificity standards, as Bédard et al 1 do, is inappropriate. The proper procedure is to engage in a cost-benefit analysis in which all of the costs of false positives and all of the costs of false negatives are taken into account before a policy decision about cut points is made. Science can inform policy decisions, but all aspects of the costs and benefits to the driver, other road users, and society need to be evaluated for informed decision making.
To conclude, we see nothing of merit in the Bédard et al 1 response to threaten our confidence in the earlier conclusion that the SIMARD MD is a marked improvement over existing screening tests for cognitively impaired, medically at-risk drivers.
Declaration of Conflicting Interests
The outcome measure used in the original and validation SIMARD MD studies is part of the DriveABLE™ Assessment. The Chief Scientific Officer of DriveABLE Assessment Centres, Dr. Allen Dobbs, is the spouse of the first author (BD). The first author has no shares in or financial relationship to DriveABLE Assessment Centres. Dr. Allen Dobbs was not involved in research on the SIMARD MD. The SIMARD MD is available to the medical and licensing communities at no charge. DS declares no competing interests.
Funding
The SIMARD MD research was supported through a grant from the Alberta Centre for Injury Control and Research.
